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“A novel multigenic immunodeficiency affecting interferon mediated immunity” 
 
ABSTRACT 
 
Primary immunodeficiencies are classically considered monogenic disorders 
characterized by host susceptibility to specific infectious pathogens. Patients with genetic 
defects in the IL-12/interferon gamma (IFN-!) axis have susceptibility to weakly virulent 
mycobacteria, Mycobacteria tuberculosis, and Salmonella, but are resistant to the majority of 
other infectious pathogens. Host susceptibility to disseminated cytomegalovirus (CMV) 
infections typically results from genetic defects in T cell development or function. We studied a 
patient with disseminated M. tuberculosis and cytomegalovirus viremia. Whole exome 
sequencing identified two novel homozygous mutations affecting two distinct IFN pathways: the 
signal transducing chain of the IFN-! receptor (IFNGR2) and the signaling chain of the IFN-" 
receptor (IFNAR1). The frameshift deletion in IFNGR2 resulted in a truncated protein with 
significantly decreased protein expression and absent downstream signaling, as demonstrated 
by a lack of STAT1 phosphorylation and HLA-DR upregulation in response to IFN-! stimulation. 
Human defects in IFNAR1 have not been previously described. The patient’s IFNAR1 mutation 
replaced the protein’s native stop codon with 46 novel C-terminal amino acids 
(IFNAR1*557Gluext*46). The IFNAR1*557Gluext*46 mutant was expressed in patient fibroblasts at a level 
comparable to that of wild-type IFNAR1 in control fibroblasts. However, the IFNAR1*557Gluext*46 
mutant led to impaired STAT1/STAT2 phosphorylation and decreased nuclear translocation of 
STAT1 in response to IFN-" stimulation. Furthermore, the patient had impaired expression of 
the IFN-" stimulated genes, IFIT1, IFIT2, and IRF7, which are critical for host immunity to CMV. 
Patient and control fibroblasts were equally susceptible to CMV entry; however, cells expressing 
 !!!"
IFNAR1*557Gluext*46 presented impaired expression of the ISG IFIT2, IFN-! and IFI16 after 
infection with CMV. Moreover, pretreatment with IFN-" did not prevent CMV replication in 
patient fibroblasts compared to cells expressing the wild type IFNAR1. The patient’s 
susceptibility to multiple types of infectious pathogens thus resulted from dual defects in Type I 
and Type II IFN signaling. These findings highlight the utility of whole exome sequencing in the 
discovery of multigenic primary immunodeficiencies.  
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1. CHAPTER 1: BACKGROUND 
 
1.1. INTRODUCTION 
 
Innate immunity constitutes the first line of host defense against infectious 
organisms1. The identification of monogenic defects in innate immunity has highlighted its 
crucial role in the normal immune response2. The innate immune response is initiated after 
sensing pathogen using a limited number of germline encoded pathogen recognition receptors 
(PRRs) that recognize pathogen-associated molecular patterns shared amongst several 
classes of infectious agents3. During viral infections, the innate immune system recognizes viral 
proteins and nucleic acids using different PRRs, which include Toll-like receptors (TLRs), RIG-I-
like receptors and DNA sensors like IFI16 and AIM24. The activation of PRRs leads to signal 
transduction pathways that activate NF-$B, the transcription factor ATF-2/c-Jun and interferon 
regulatory factors (IRF) 1, 3 and 75, culminating in expression of genes important for host 
immunity, including those encoding for type I interferons.  
Interferons (IFN), originally discovered by Isaacs and Lindenmann in 19576, are proteins 
secreted by the host’s cells upon infection. There are three families of IFNs: type I (IFN-", IFN-% 
and IFN-&), type II (IFN-!), and type III (IFN-'1, IFN-'2 and IFN-'3). Each type of IFN has its 
specific receptor (IFNAR, IFNGR, IFNLR) and distinctive signaling pathway. Additionally, 
crosstalk exists among the IFN signaling pathways. Although the type I IFN receptor (IFNAR) 
signals primarily through heterodimers of STAT1 and STAT2 transcription factors, IFNAR also 
signals through STAT1 homodimers, which is a signaling pathway classically associated with 
the IFN-! receptor  (IFNGR)7. The crosstalk between the IFNR signaling pathways can also be 
initiated by the IFNGR, which can alternatively signal via STAT1 and STAT2 heterodimers8. The 
most widely studied function of the IFNs is their role in the protective response against viral 
infections by inducing the cellular antiviral response. Stimulation of the IFNAR and to some 
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extent the IFNGR, allow the initiation of the antiviral state in several cell types. Cross talk 
between the IFNAR and IFNGR signaling pathways allows IFN-! to induce the expression of a 
limited number interferon stimulated genes (ISG); however, type I IFNs are the most potent 
inducers of the antiviral response and stimulate the expression of a bigger number of ISG9. 
The genes coding for type I IFNs are clustered in one locus on the human chromosome 
9 and include 13 genes coding IFN-", 1 gene coding for IFN-% and 1 gene coding IFN-&10. 
Type I IFNs constitute a major component of the innate immune response against viral 
infections and are rapidly induced after sensing of viral proteins or nucleic acids by the PRRs. 
Type I IFNs produced during early phases of infection stimulate the IFNAR in both an autocrine 
and a paracrine fashion, activating the transcription of ISGs important for establishing antiviral 
defense and amplifying type I IFN production via a positive feedback mechanism11. 
The IFNAR is a complex consisting of two receptor subunits, IFNAR1 and IFNAR212, the 
receptor associated kinases Tyk2 and Jak1, and the IFNAR2 associated signaling protein 
STAT213 (Schematic Figure 1). IFNAR1 is a transmembrane protein of 557 aminoacids coded 
by the IFNAR1 gene, has low affinity for type I IFNs and acts as the signaling chain of the 
IFNAR14. IFNAR2 is a transmembrane protein with three described isoforms (IFNAR2c, 
IFNAR2b, sIFNAR2a)15, all of them encoded in a single IFNAR2 gene in chromosome 21 and 
generated by means of exon skipping, alternative splicing and differential usage of 
polyadenylation sites. The functional isoform of the IFNAR2 protein, IFNAR2c, has high affinity 
for type I IFNs and acts as the ligand binding chain of the IFNAR, while IFNAR2b and 
sIFNAR2a have a modulatory function on the response to type I IFNs14. 
Intracellular signaling downstream of the IFNAR is initiated upon binding of the type I 
IFNs, resulting in activation of the receptor associated kinases Jak1 and Tyk2 (Schematic 
Figure 1). These kinases phosphorylate the intracellular portion of IFNAR1, thereby creating a 
docking site for STAT2. STAT2 translocates from the IFNAR2 chain to the IFNAR1 chain and is 
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subsequently phosphorylated by Tyk2 and Jak1, which enables STAT1 binding (Schematic 
Figure 1). STAT1 is then activated by phosphorylation and causes the release of the 
phosphorylated STAT1/STAT2 heterodimer (pSTAT1/pSTAT2) from IFNAR1. pSTAT1/pSTAT2 
binds to IRF-9 in the cytoplasm, forming a trimer known as IFN stimulated gene factor 3 
(ISGF3), which then translocates to the nucleus and binds to the IFN stimulated response 
element (ISRE) within the promoter of ISGs to activate the transcription of hundreds of genes 
(Schematic Figure 1)13, 16. The importance of the response to type I IFNs in controlling viral 
infections has been recently highlighted by the description of human mutations in the genes 
encoding IFNAR2 and STAT2. These patients exhibit complete abrogation of the response to 
type I IFNs and developed fatal infections with vaccine strain measles after inoculation with the 
live attenuated measles, mumps and rubella vaccine (MMR)17, 18. These patients were not 
susceptible to other viruses, including cytomegalovirus (CMV), Epstein-Barr virus (EBV), 
varicella zoster virus (VZV), and multiple respiratory viruses, suggesting that the type I IFNs 
have a contribution to host immunity against specific viral pathogens.  
IFN-! is the sole member of the type II IFN family. IFN-! is structurally unrelated to the 
type I IFN family and binds to its own receptor (IFNGR)10. In contrasts to the type I IFNs, 
produced by most cell types, IFN-! is exclusively produced by immune cells: CD4+ T cells, CD8+ 
T cells, NK cells, NKT cells, monocytes, macrophages and dendritic cells8. During the initial 
phases of infection, pathogen recognition by monocytes and macrophages induces the 
production of chemokines and IL-12. Recruited NK cells produce IFN-! in response to IL-12 at 
site of infection and provide the initial source of IFN-! during the innate phase of the immune 
response19, while T cells are the most important source of IFN- ! during the adaptive phase. 
The IFNGR is a four-chain complex, composed of two ligand binding chains (IFNGR1) 
and two signal transducing chains (IFNGR2) (Schematic Figure 2). The IFNGR2 chain, while 
critical for signaling downstream of the IFNGR, does not bind directly to IFN-! and is not 
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capable of initiating signaling in absence of IFNGR120, 21. The abundance of each chain varies 
within different cell types and with the activation state of the cell, but overall, the cell’s 
responsiveness to IFN-! is determined primarily by the surface expression of IFNGR2. Like the 
chains of the IFNAR, IFNGR1 and IFNGR2 lack intrinsic enzymatic activity and depend on the 
association with the tyrosine kinases Jak1 and Jak2 to initiate downstream signaling events8 
(Schematic Figure 2).  
Signaling downstream of the IFNGR begins after IFN-! binds to the IFNGR1 chain 
(Schematic Figure 2). Subsequent auto-phosphorylation of Jak1 and trans- phosphorylation of 
Jak2 enables phosphorylation of critical cytoplasmic residues (YDHPK at amino acids 440-444) 
on both IFNGR1 chains, which serve as docking sites for STAT18. After binding to IFNGR1, the 
recruited STAT1 proteins undergo phosphorylation at Tyr701 and dissociate from the receptor as 
a pSTAT1 homodimer known as IFN-! activated factor (GAF). The GAF translocates to the 
nucleus and binds to IFN-! activation sites (GAS) within the promoter of IFN-! regulated genes 
to activate or suppress transcription8, 22. In addition to signaling through the canonical GAF 
pathway, the IFNGR can signal to a lesser extent via pSTAT1:pSTAT1:IRF-9 heterotrimers and 
ISGF3 complexes to induce the expression of ISGs8 (Schematic Figure 2). 
Although the specific antiviral function of many ISGs have yet to be studied, the IFN-
induced protein with tetratricopeptide repeats (IFIT) family of ISGs has been well characterized. 
The human IFIT family is composed of four genes: IFIT1, IFIT2, IFIT3 and IFIT5, none of which 
are constitutively expressed23. The presence of ISRE sequences in the promoter region of the 
IFIT genes enables rapid and robust expression in response to type I IFNs produced during the 
early stages of viral infections24. All IFIT proteins are cytoplasmic and contain tetratricopeptide 
motifs that facilitate binding to host and viral proteins, thereby enabling them to block viral 
replication25. IFIT1 and IFIT2 block the initiation of translation by binding to the eukaryotic 
initiator factor eIF3 and decrease viral replication by decreasing cellular translation itself26. 
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Besides decreasing cellular translation, IFIT1 blocks viral replication more specifically by 
interacting with viral proteins. For example, IFIT1 binds and sequesters the human papilloma 
virus helicase E1 in the cytoplasm and effectively reduces the viral replication process27. The 
IFIT family of proteins also blocks viral replication by interacting with viral nucleic acids. During 
infection with negative stranded RNA viruses, IFIT1 recognizes and binds to the virus uncapped 
5’ triphosphate RNA and provides a scaffold for IFIT2 and IFIT3 to form a complex that 
sequesters viral RNA and decreases the pool of actively replicating viral nucleic acids28. Due to 
its important role in the antiviral response and their upregulation upon IFNAR signaling, 
expression of the IFIT genes is commonly used to evaluate the cellular response to exogenous 
type I IFNs29 or viral infections30. 
The description of Mendelian susceptibility to mycobacterial diseases (MSMD), a group 
of monogenic PID affecting the IL-12/IFN-! axis, has demonstrated the importance of type II 
IFNs in host immunity. Mutations underlying MSMD have been found in six genes (IFNGR1, 
IFNGR2, IL12B, IL12RB1, STAT1 and NEMO) and result in thirteen disorders that differ in their 
inheritance pattern, levels of protein expression and overall functionality of the IL-12/IFN-! 
axis31, 32. MSMD patients can be further classified based on the cellular response to IFN-! 
stimulation, as having complete (no response) or partial (residual response) forms of the 
disease33. Patients with MSMD are predisposed to infections with weakly virulent mycobacteria, 
such as Mycobacterium bovis in the Bacillus Calmette-Guérin (BCG) vaccine, as well as 
Mycobacterium tuberculosis and Salmonella33. Patients with defects in the IL-12/IFN-! axis are 
usually resistant to infections caused by most other infectious pathogens. However, individual 
case reports have identified patients with additional concomitant infections, including 
listeriosis34, klebsiellosis35, nocardiosis36, 37, histoplasmosis38, paracoccidioidomycosis39, VZV 
and CMV40. It is not kwon if these atypical infections occurred because of an additional role of 
the IL-12/IFN- ! axis in host defense against these organisms, or from patient-specific genetic 
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variations affecting other mechanisms of host immunity. We here present a patient who 
presented with disseminated mycobacterial, streptococcal and cytomegalovirus infections 
resulting in secondary hemophagocytic lymphohistiocytosis. Using whole exome sequencing 
(WES) we have identified two novel pathogenic mutations that affect the IFNGR2 and the 
IFNAR1 genes in this patient. To our knowledge, this is the first description of an 
immunodeficiency affecting the response to both type I IFNs and IFN-!, as well as the first 
description of a pathogenic mutation affecting the IFNAR1 gene in humans. Our studies 
highlight the utility of WES in the discovery of multigenic primary immunodeficiencies. 
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1.2. SCHEMATIC FIGURES 
Schematic Figure 1. Model of the IFNAR signaling pathway. 
 
The IFNAR is composed of two chains, IFNAR1 and IFNAR2c. Upon IFN" binding to the 
receptor, the receptor pre-associated kinases Tyk2 and Jak1 phosphorylate the intracellular 
domains of the receptor creating a docking site for STAT2 at the IFNAR1 chain. STAT2 is 
phosphorylated and recruits STAT1, STAT1 is activated by phosphorylation and the 
pSTAT1/pSTAT2 dimer is released to the cytoplasm where binds with IRF9 to form the IFN 
stimulated gene factor 3 (ISGF3) complex. ISGF3 translocates to the nucleus and binds to the 
IFN stimulated response elements (ISRE) sequences in the promoter region of ISG and 
activates gene expression. 
 
 +"
Schematic Figure 2. Model of the IFNGR signaling pathway. 
 
The IFNGR is composed of two chains, IFNGR1 and IFNGR2. Upon binding of IFN! to 
the IFNGR1 chain, the kinases Jak1 and Jak2 activate each other by cross-phosphorylation. 
The kinases then phosphorylate the intracellular domain of the IFNGR1 chain creating a 
docking site for STAT1. STAT1 binds to Tyr457 of each IFNGR1 and is phosphorylated by the 
Jak kinases. The pSTAT1 proteins form a dimer known as gamma activating factor (GAF) and 
are released from the receptor. The GAF then translocates to the nucleus and binds to IFN! 
activation sites (GAS) in the promoter region of IFN! regulated genes to induce gene 
expression.  
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2. CHAPTER 2: METHODS AND DATA 
 
2.1. INTRODUCTION 
 
 We studied a two months old boy presenting with simultaneous disseminated 
Mycobacterium tuberculosis, CMV and Streptococcus viridans infection causing secondary 
HLH. Due to the simultaneous isolation of multiple infectious agents and the atypical 
development of secondary HLH, this patient was thought to have an underlying primary 
immunodeficiency. To perform genetic studies in this patient, blood samples were obtained and 
prepared for DNA isolation and WES analysis. To functionally prove the pathogenic nature of 
the mutations found by WES, a skin biopsy was obtained to establish a fibroblast cell line. 
Immunoblotting, flow cytometry and qt-PCR techniques were used to evaluate the cellular 
response to IFN stimulation. To further test the cell’s anti-viral response, mutant and control 
skin derived fibroblasts were subjected to infection with CMV.   
  
2.2. MATERIALS AND METHODS 
 
Study participants 
 
The proband and his parents were enrolled in this study. After informed consent, 
peripheral blood was obtained from the study participants; a skin biopsy was obtained from the 
proband to generate a fibroblast cell line. All studies performed on blood or skin derived 
fibroblasts from the study participants were approved by Boston Children’s Hospital Institutional 
Review Board (Protocol 04-09-113R).  
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Genetic analysis 
 
Genomic DNA was isolated from peripheral blood samples of the proband using the 
Gentra Puregene Blood Kit (Qiagen) as per kit protocol. WES was performed by Illumina 
HiSeq-2000 (Illumina Inc., San Diego, CA) on the proband. The paired-end Illumina libraries 
were captured in solution according to the Agilent SureSelect protocol. Average coverage of the 
exome was 150x. The Burrows-Wheeler Aligner (BWA) was used to map reads to the human 
reference genome assemby GRCh3741. Variants were called using the Genome Analysis 
Toolkit (GATK)42, Sam Tools43, 44 and Picard tools (http://picard.sourceforge.net) 
 
Sanger sequencing 
 
 Sanger sequencing was used to validate the mutations in the IFNGR2 and IFNAR1 
genes identified on the proband by WES and to identify the carrier status of the parents. Two 
pairs of gene specific nested primers were used to cover the mutation site in each gene: 
IFNGR2 (F1: 5’-GTGAGAAGAGTGCTGAACTG-3’; F2: 5’-GTGCGTAGGAAGATCATTCT-3’; 
R1: 5’-ACCATTAAGATGTCTGCGTG-3’; R2: 5’- AGAGATTGTACCATGACACT-3’), IFNAR1 
(F1: 5’-TAGTATTTCTCTGAACAGCCAT-3’; F2: 5’-TCAACTTCTGAGGAACAAATCG-3’; R1: 5’-
TGACTCATCTCATCCAATGC-3’; R2: 5’-GACCTATGATCTGAAGATGT-3’). 
 
cDNA sequencing 
 
 RNA from skin derived fibroblasts was extracted using the RNeasy Mini Kit (Qiagen) and 
was reverse-transcribed with the OneStep RT-PCR kit (Qiagen) as per kit protocol. cDNA was 
sequenced with nested IFNGR2C266fs (F1: 5’-CTTTGACATCGCTGATACCTC-3’; F2: 5’-
CTCCAGAGTGTACTGTTTACA-3’; R1: 5’-AAGCGTTTGGAGAACATCTTCT-3’; R2: 5’-
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GAACATCTTCTTGCTCCTTTT-3’) or IFNAR1*557next*46 specific primers (F1: 5’-
TTCTCTGAACAGCCATTGAAGAA-3’; F2: 5’-GCTACAGTAGAAGAAACTAAT-3’; R1: 5’-
TTAGGACCTATGATCTGAAGATGT-3’; R2: 5’-TCTGACTCATCTCATCCAATGC-3’).  
 
Cell-culture and stimulation conditions 
 
Fibroblasts were maintained in DMEM supplemented with 10% fetal bovine serum, 
50,000IU penicillin, 50,000µg streptomycin, 10µM HEPES, and 2mM Glutamine. PBMCs were 
isolated using Ficoll solution then were cultured in RPMI medium supplemented with 10% fetal 
bovine serum, 50,000IU penicillin, 50,000µg streptomycin, 10µM HEPES, and 2mM Glutamine 
overnight. Cells were stimulated with IFN-" or IFN-! (R&D systems) 1000IU/mL for the 
described time points. 
Fibroblasts were seeded at a density of 1x105 cells/well in 6 well plates and 48 hours 
later were stimulated with IFN-" or IFN-!. For immunoblotting experiments, cells were 
stimulated for 15, 30 or 60 minutes with the corresponding IFN. For subcellular fractionation and 
gene expression experiments, cells were stimulated for 8, 16 or 24h with IFN-". 
 
Immunoblotting 
 
Cultured skin fibroblasts were homogenized in PBS that contains 30mM Tris-HCl pH 7.5, 
120mM NaCl, 2mM KCl, 1% Triton X-100 and 2mM EDTA supplemented with protease and 
phosphatase inhibitors (Complete and PhoStop, Roche). Proteins were separated by 
electrophoresis on 4-15% precast polyacrylamide gels (Bio-Rad) and were transferred to 
0.45µm nitrocellulose membrane (Bio-Rad). Membranes were blocked in a 1x solution Tris-
Buffered Saline/Tween 20 (TBST) with 5% (w/v) nonfat dry milk for one hour at room 
temperature and then incubated overnight at 4°C with purified rabbit polyclonal antibody against 
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pSTAT2-Tyr690 (Cell signaling, 4441), pSTAT1-Tyr701 (Cell signaling, 9167) diluted 1:1000 or 
1:2000, respectively, in 1x TBST with 5% BSA. Immunoblot detection of IFNAR1 was done with 
a purified rabbit polyclonal antibody (Bethyl, A304-289A) diluted 1:800 in 1x TBST with 5% milk. 
As a loading control, membranes were re-probed with a purified mouse monoclonal antibody 
against %-actin (Abcam, ab3280) diluted 1:20000 in 1x TBST with 5% milk or a purified 
polyclonal rabbit antibody against STAT1 (Cell signaling, 14995) or STAT2 (Cell signaling, 
4594) diluted 1:1000 in 1x TBST with 5% BSA. Antigen-antibody complexes were visualized 
with anti-rabbit or anti-mouse secondary antibodies respectively (GE Healthcare). Quantification 
of the signal intensities of pSTAT1, pSTAT2, STAT1, STAT2, was done using the ImageJ 
analyzer software (1.48v). 
 
Subcellular fractionation 
 
 To assess pSTAT1 nuclear translocation after 8 or 24h of stimulation with IFN-", cells 
were subjected to subcellular fractionation using a Nuclear Fractionation Kit (Active motif) as 
per kit protocol. pSTAT1 nuclear translocation was determined by immunoblotting and 
quantified as previously described. As loading controls for each subcellular fraction, 
membranes were probed with a polyclonal antibody against Rab5 (Cell signaling, 2143) diluted 
1:400 in 1X TBST with 5% milk or PARP (Cell signaling, 9532) diluted 1:200 In 1X TBST with 
5% milk for the cytoplasmic and nuclear fraction, respectively.  
 
Gene expression analysis 
 
After 8, 16 or 24h of stimulation with IFN-" (1000IU/ml), RNA was extracted from skin 
derived fibroblasts using the RNeasy Mini Kit (Qiagen) and was reverse-transcribed with the 
iScript cDNA synthesis kit (BioRad). To measure gene expression after IFN-" stimulation, 
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expression of the ISGs IFIT1 (Hs00356631_g1), IFIT2 (Hs01922738_s1) and IRF7 
(Hs01014809_g1) and the housekeeping gene GUSB (Hs00939627_m1 Life Technologies, 
USA) was measured. Results were analyzed using the 2-((CT method. 
For gene expression analysis following viral infections, total RNA was harvested from 
mock-, HSV-1 d109 or HCMV-infected cells using the RNeasy kit (Quiagen) and DNase treated 
(DNA-free, Ambion) according to the manufacturer’s instructions. RNA (500 ng) was reverse 
transcribed with a High-Capacity cDNA Reverse Transcription Kit (Life Technologies), and 
cDNA was analyzed by real-time PCR (Step One Plus, Applied Biosystems) using Power SYBR 
green mix. Samples were normalized to cellular 18S RNA levels. For PCR using DNA, viral 
DNA copy numbers were normalized to a cellular GAPDH pseudogene. The primers used in this 
study are as follows: Human IFN%: (Fp: 5’-AAACTCATGAGCAGTCTGCA-3’; Rp: 5’-
AGGAGATCTTCAGTTTCGGAGG-3’), Human IFIT2 (Fp: 5’-ACGGTATGCTTGGAACGATTG-
3’; Rp: 5’-AACCCAGAGTGTGGCTGATG-3’), 18S RNA (Fp: 5’-GCATTCGTATTGCGCCGCTA-
3’; Rp: 5’-AGCTGCCCGGCGGGT-3’), GAPDH (Fp: 5’- CAGGCGCCCAATACGACCAAATC-3’; 
Rp: 5’-TTCGACAGTCAGCCGCATCTTCTT-3’), Human IFI16 (Fp: 5’-
ACTGAGTACAACAAAGCCATTTGA-3’; Rp: 5’-TTGTGACATTGTCCTGTCCCCAC-3’), IE1 (Fp: 
5’-CAAGTGACCGAGGATTGCAA-3’; Rp: 5’-CACCATGTCCACTCGAACCTT-3’), CMVexon4 
(Fp: 5’-GATAGTCGCGGGTACAGGGGACTCT-3’; Rp: 5’-
GGTCACTAGTGACGCTTGTATGATGACCATCTACGG-3’)  
 
Fluorescence-activated cell sorting (FACS) analysis 
 
Standard flow cytometric methods were used for staining of cell-surface proteins. Anti-
human mAbs to the following molecules with the appropriate isotype-matched controls were 
used for staining: CD14 (Biolegend, 325606), HLA-DR (Biolegend, 307617) and IFNGR2 (R&D 
systems, FAB773). IFNGR2 studies were done on PBMCs. For HLA-DR upregulation studies, 
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fibroblasts were cultured at a density fo 1x105 cells/well in 6 well plates and stimulated with IFN-
! 1000IU/mL for 4 days before staining. For STAT1 phosphorylation studies, fibroblasts were 
cultured at a density fo 1x105 cells/well in 6 well plates and stimulated with IFN-" 1000IU/mL for 
1, 3, 5, 15, 30, 45 or 60 minutes. For intracellular staining experiments, BD Phosflow Lyse/Fix 
Buffer and Phosflow Perm Buffer III (BD biosciences) were used as per kit protocol, an anti-
human mAb to pSTAT1 (Cell signal, 9174) with the appropriate isotype-matched control was 
used for staining. 
All flow cytometry data was collected with an LSRFortessa (BD Biosciences, San Jose, 
Calif) cell analyzer and analyzed with FlowJo software (Tree Star, Ashland, Ore). 
Viral infection 
 The HCMV laboratory strain AD169 was obtained from the NIH AIDS Reagent Program, 
and was propagated in human foreskin fibroblasts (HFF) as described45. The HSV-1 replication-
defective virus d109 lacking expression of immediate-early genes was grown and titrated as 
previously described46. For infections, viruses were diluted in PBS containing 1% BCS and 0.1% 
glucose and incubated with cells for 1.5 h on a 37°C shaker. Cells were infected at a multiplicity 
of infection (MOI) of 1. After viral adsorption, the cells were washed with PBS and overlaid with 
DMEM supplemented with 10% FBS. For viral entry studies, cells were infected at a MOI of 10 
and DNA was isolated immediately after viral adsorption. 
Immunofluorescence  
 Fibroblasts grown on glass coverslips were mock- or HCMV-infected and fixed with 2% 
formaldehyde at the indicated times post infection. Coverslips were permeabilized with 0.5% NP-
40 for 10 min and blocked in DMEM containing 5% normal goat serum for 1 h at room 
temperature. The cover slips were incubated with mouse anti-IE antibody (1:500, Millipore) 
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followed by a secondary anti-mouse Alexa-488 antibody (1:1000; Jackson ImmunoResearch).  
Nuclei were counterstained with DAPI. Cells were imaged using an Axioplan 2 microscope 
(Zeiss) at 40x magnification.  
Statistical analysis 
All data is presented as mean ± S.E.M, and compared using the unpaired t-test or two-
way ANOVA. Statistical analysis was performed using GraphPad Prism software (version 6.0).  
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2.3. RESULTS 
 
Clinical presentation and immunologic phenotyping 
 
The proband is the son of consanguineous parents of Saudi Arabian ancestry. There 
was no family history of PID. Healthy until two months of age, when he presented with a two-
week history of poor feeding, lethargy and fever. His blood culture was positive for 
Streptococcus viridans. He developed splenomegaly, lymphadenopathy, thrombocytopenia, 
anemia, and elevated ferritin levels consistent with secondary HLH (Supplementary Table 1). 
Histologic evaluation of his bone marrow revealed hemophagocytosis. Cultures of his bone 
marrow and lymph nodes were positive for Mycobacterium tuberculosis. At this time, he was 
also found to have CMV viremia (4,000,000 copies/mL). Immunological evaluation was normal 
(Table1) and HIV PCR was negative. Sanger sequencing of genes associated with familial HLH 
(PRF1, UNC13D, STX11, STXBP2) was normal. He was treated with dexamethasone and 
cyclosporine for HLH and gancyclovir for CMV viremia. His mycobacterial infection was treated 
with isoniazid, rifampin, clarithromycin, ciprofloxacin and amikacin.  The patient has been 
healthy on prophylactic anti-tuberculosis medications and has received attenuated viral 
vaccines without development of vaccine-associated diseases. 
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Table 1. Immune profile of the patient 
 
Lymphocyte subsets, cells/mL (normal range for age)47  
CD3+  5,250 (2,500 – 5,500) 
  CD3+CD4+ 1,180 (1,600-4,000) 
  CD3+CD8+ 3,610 (560 – 1,700) 
  CD4+/CD8+ 0.32 
CD19+ 2,390 (300 – 2,000) 
  CD19+HLA-DR+ 100% 
CD16+/CD56+  1,100 (170 – 1100) 
Immunoglobulins, mg/dL (normal range)48  
   IgG 670 (206 – 601) 
   IgA  40 (2.8 – 47) 
   IgM 90 (17-105) 
Lymphocyte proliferation (% of normal control)  
   Phytohaemagglutinin 76 
   Concavalin A 36 
   Pokeweed 143 
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Identification of homozygous mutations in IFNGR2 and IFNAR1 
  
Due to the consanguinity of the proband’s parents, we anticipated an autosomal 
recessive cause of immunodeficiency. WES of the proband revealed 37 homozygous variants 
(Supplementary Table 2), which were not found in multiple public databases or our own in-
house database of exomes.  
A homozygous one base pair deletion in IFNGR2 (IFNGR2C266fs, 
NM_005534:c.798delT:p.C266fs) was considered a plausible causative variant due to the 
known contribution of IFN- ! in host defense against mycobacteria. IFNGR2C266fs is predicted to 
cause a frameshift followed by premature truncation of the protein after residue 270, which 
resides in the intracellular domain of IFNGR2 (Figure 1A). Additionally, a homozygous mutation 
in the IFNAR1 gene (IFNAR1*557Gluext*46, NM_000629:c.1671_1821del: p.*557Gluext*46) was 
also identified in this patient. The IFNAR1*557Gluext*46 mutation is predicted to disrupt the protein’s 
stop codon, leading to the addition of 46 novel aminoacids to the protein’s C terminus (Figure 
1C). Sanger sequencing of genomic DNA confirmed that both mutations were present in the 
homozygous state in the proband and in the heterozygous state in both parents (Figure 1 and 
Supplementary Figure 1). 
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Figure 1. Predicted effect in protein structure and Sanger sequencing of the IFNGR2 and 
IFNAR1 mutations. 
 
 
 
A, Schematic of wild type (WT) and mutant (IFNGR2C266fs) IFNGR2. The IFNGR2C266fs protein is 
truncated at residue 270.  B, Sanger sequencing demonstrating the IFNGR2 mutation (798delT) 
in the homozygous state in the patient. Sequencing of a control subject is included. C, 
Schematic of wild type (WT) and mutant (IFNAR1*557next*46) IFNAR1 protein. The IFNAR1*557next*46 
protein has 46 extra aminoacids at the protein C terminus.  D, Sanger sequencing 
demonstrating the IFNAR1 mutation (1671_1821del) in the homozygous state in the patient. 
Sequencing of a control subject is included. EC = extracellular domain, TM = transmembrane 
domain, IC = intracellular domain, NS = novel sequence.  
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Impaired response to IFN-! in fibroblasts expressing IFNGR2C266fs  
 
The intracellular domain of IFNGR2 contains the binding site for the kinase Jak2. The 
association of IFNGR2 and Jak2 is critical for intracellular signaling downstream of the receptor 
after IFN-! binding to the IFNGR20, 21. The premature stop codon in IFNGR2C266fs would result in 
a mutant protein lacking the binding site for Jak2. This was confirmed by Sanger sequencing of 
cDNA generated by RT-PCR of mRNA from the patient’s fibroblasts (Supplementary Figure 2A). 
We next evaluated the effect of IFNGR2C266fs on protein expression. IFNGR2 surface expression 
was evaluated by flow cytometric anaysis using an antibody specific to the protein’s N-terminus. 
Monocytes from the proband exhibited severely decreased expression of the mutant 
IFNGR2C266fs protein compared to expression of the native protein on control monocytes (Figure 
2A). We aimed to confirm the effect of the IFNGR2C266fs mutation at the protein level by 
immunoblotting, however, analysis of the IFNGR2 expression on fibroblasts was not possible 
using comercially available antibodies directed against the protein N terminus.  
Stimulation of the IFNGR complex with IFN-! leads to phosphorylation of STAT2 and 
upregulation of the MHC class II protein HLA-DR on fibroblasts. Patient fibroblasts had 
complete abrogation of STAT1 phosphorylation and no upregulation of HLA-DR after IFN-! 
stimulation (Figure 2B and 2C). This data demonstrates that the 67 C-terminal residues in 
IFNGR2 are essential for receptor signaling.  
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Figure 2. Analysis of the expression and functionality of the mutant IFNGR2C266fs protein. 
 
 
A, Flow cytometric analysis of the wild type and mutant IFNGR2 protein expression at the 
surface of CD14+ cells from a healthy control (WT IFNGR2) and the proband (IFNGR2C266fs). B, 
Inmunoblot analysis of STAT1 phosphorylation after IFN-! stimulation in lysates of skin derived 
fibroblasts from the proband and healthy controls. C, Flow cytometric analysis of the HLA-DR 
expression at the cell surface of skin derived fibroblasts from the proband and healthy control 
after IFN-! stimulation. 
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IFNAR1*557Gluext*46 preserves protein expression and adds a novel 46 amino acid sequence 
to the C-terminus of IFNAR1 
 
 The proband’s history of disseminated CMV is not typical for a defect in IFNGR, since 
CMV infections have been previously reported in only three patients with mutations affecting the 
IL-12/IFN-! axis. In addition to the mutation in IFNGR2, the proband we present also had a 
novel mutation in IFNAR1. IFNAR1 functions as the signaling chain of the IFNAR and is 
required for responsiveness to type I IFNs. Due to the known importance of the type I IFNs in 
controlling viral infections, we investigated the effect of the patient’s IFNAR1*557Gluext*46 on 
IFNAR1 expression and signaling. The IFNAR1*557Gluext*46 mutation is predicted to disrupt the 
native stop codon and add 46 novel C-terminal amino acids with a molecular weight of an 
additional 5 kilo Daltons, while otherwise preserving the normal IFNAR1 protein sequence. 
Immunoblotting of fibroblast lysates from the patient using an antibody targeting aminoacids 
450-500 of IFNAR1 C-terminus, revealed expression of IFNAR1*557Gluext*46 protein at a level 
comparable with that of WT IFNAR1 in control fibroblasts (Figure 3A). Since the increase of 5 
kilo Daltons in the molecular weight of the mutant IFNAR1 was not distinguishable on 
immunoblotting, the sequence of the novel 46 C-terminal amino acids was confirmed by Sanger 
sequencing cDNA generated from mRNA isolated from the patient’s fibroblasts (Supplementary 
Figure 2B). 
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Figure 3. Analysis of the expression and functionality of the mutant IFNAR1*557next*46 
protein. 
 
 
A, Immunoblot analysis of IFNAR1 in lysates of skin derived fibroblasts from the proband 
(Mutant) and healthy controls (WT). B, Inmunoblot analysis of STAT1 phosphorylation after 
IFN" stimulation in lysates of skin derived fibroblasts from the proband (IFNAR1*557next*46) and 
healthy controls (WT IFNAR1). C, Quantitative analysis of STAT2 phosphorylation. * P < 0.05; 
** P < 0.01 by unpaired t test. D, Flow cytometric analysis of STAT1 phosphorylation after IFN" 
stimulation in skin derived fibroblasts from the proband and healthy controls. The means and 
SEs of three independent experiments are shown. **** P < 0.0001 by two way ANOVA.   
E, Inmunoblot analysis of pSTAT1 nuclear translocation after IFN" stimulation of skin derived 
fibroblasts from the proband and healthy controls. After IFN" stimulation, fibroblasts were 
fractionated into cytoplasmic (C) and nuclear (N) fractions.  
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Figure 3 (Continued) F, Quantitative analysis of pSTAT1  nuclear translocation. pSTAT1 density 
in each fraction was normalized to the corresponding loading control and added to obtain total 
pSTAT1. pSTAT1/Total pSTAT1 represents pSTAT1 distribution between the C and N fractions. 
Columns and bars represent means and SEMs and are representative of three experiments. * P 
<0.05 by unpaired t test. 
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Defective intracellular signaling downstream of IFNAR1*557Gluext*46 
 
Binding of IFN-α to the IFNAR complex leads to STAT2 activation and subsequent 
STAT1 phosphorylation. Assembly of the pSTAT1/pSTAT2 heterodimer triggers a cascade of 
intracellular signaling events that ultimately induce the ISGs necessary for controlling viral 
replication7 and spread49. We first investigated the patient’s cellular response to IFN-" by 
quantifying STAT2 and STAT1 phosphorylation downstream of IFN-" stimulation in fibroblasts. 
Although the mutant IFNAR1*557Gluext*46 protein preserves all necessary docking sites required for 
downstream intracellular signaling events, STAT2 phosphorylation, as quantified by 
immunoblotting, was significantly decreased after IFN-" stimulation of the patient’s fibroblasts 
(Figure 3B-C). Flow cytometric analysis of STAT1 phosphorylation was also decreased after 
IFN-" stimulation of the patient’s fibroblasts (Figure 3D), as would be expected in the setting of 
impaired STAT2 phosphorylation. After phosphorylation of receptor associated STAT1 and 
STAT2, the pSTAT1/pSTAT2 heterodimer is released to the cytoplasm and associates with IRF-
9 to form ISGF3 complexes that translocate to the nucleus. Since after IFN-α stimulation, 
pSTAT1 exists in the nuclear compartment mostly as part of the ISGF3 complex, we assessed 
the subcellular distribution of pSTAT1 after IFN-α stimulation in patient and control fibroblasts. 
Compared to controls, an increased proportion of pSTAT1 was retained in the cytoplasm of 
patient fibroblasts 8 and 24 hours after IFN-α stimulation (Figures 3E-F), suggesting that the 
presence of the additional 46 aminoacids at the C terminus in IFNAR1*557Gluext*46 stabilizes the 
interaction between the receptor and the pSTAT1/pSTAT2 dimer. Collectively, these data 
indicate that the novel 46 amino acids in the mutant IFNAR1*557Gluext*46 receptor result in impaired 
phosphorylation of STAT1 and STAT2 as well as defective nuclear translocation of 
pSTAT1/pSTAT2 heterodimers. 
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Impaired ISG upregulation downstream of IFNAR1*557Gluext*46 
  
 Nuclear translocation of the STAT1/2 heterodimer is followed by the expression of genes 
important for the anti-viral response. Some ISGs like IFIT1 and IFIT2 are important for blocking 
viral replication by decreasing cellular translation and interacting directly with viral proteins, 
while other ISGs like IRF7 are important for amplifying type I IFNs production or pathogen 
recognition like IFI16. Since the proband presented with disseminated CMV, we evaluated the 
expression of IFIT1, IFIT2, and IRF7 after IFN-" stimulation of patient and control fibroblasts. 
Induction of IFIT1, IFIT2, and IRF7 was significantly decreased in the patient’s fibroblasts 
compared to control cells (Figure 4A). Notably, the expression of IFIT1 and IFIT2 is exclusively 
controlled by type I IFNs24 and fibroblasts do not secrete IFN-!. Therefore, these data 
demonstrate that the mutant IFNAR1*557Gluext*46 receptor significantly impairs the induction of 
genes critical for control of viral expansion and that the patient’s IFNGR2C266fs mutation does not 
contribute to the diminished expression of IFIT1, IFIT2, and IRF7 after IFN-" stimulation. 
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Figure 4. IFNAR1*557next*46 results in decreased expression of ISG after IFN" stimulation 
and viral infection. 
 
 
A, Skin derived fibroblasts from the proband (IFNAR1*557next*46) or healthy controls (WT IFNAR1) 
were stimulated with IFN" and ISG expression was evaluated by qt-PCR. The means and SEs 
of three independent experiments are shown. * P < 0.05; ** P < 0.01 by two way ANOVA. B, 
Skin derived fibroblasts from the proband (IFNAR1*557next*46) or healthy controls (WT IFNAR1) 
were infected with CMV or HSV-1 d109 for 4 hours after which ISG expression was evaluated 
by qt-PCR. * P < 0.05; *** P < 0.001 
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Impaired upregulation of ISGs after CMV infection and defective anti-viral state in 
fibroblasts expressing IFNAR1*557Gluext*46 (*) 
 
The expression of ISGs is important for establishing the cellular anti-viral response and 
blocking the viral replication and protein expression. We have shown that upregulation of ISGs 
is diminished in cells expressing IFNAR1*557Gluext*46 after stimulation with IFN-". To prove the 
biological significance of these findings, we next evaluated the upregulation of ISGs after 
infection with CMV or the Herpes simplex virus-1 (HSV-1) d109, a potent inducer of the type I 
IFN response.  Induction of the ISGs IFIT2, IFN-! and IFI16 was significantly decreased in 
fibroblasts expressing IFNAR1*557Gluext*46 compared to control cells after infection (Figure 4B). 
The decreased upregulation of ISGs observed after infection with CMV or HSV-1 d109 is not 
explained by different expression of PRRs important for sensing infection with herpes viruses or 
differences in viral entry, as shown by similar baseline expression of the DNA sensor IFI16 and 
quantification of the CMV IE1 gene after viral adsorption (Supplementary Figure 3A and B).  
We next evaluated the effectiveness of the anti-viral state induced by type I IFNs to block 
CMV replication in patient and control fibroblasts. Pre-treatment with IFN-" completely 
abrogated the expression of the CMV derived proteins IE1 and IE2, a maker of viral replication, 
in control fibroblasts while it had no effect in fibroblasts expressing IFNAR1*557Gluext*46 (Figure 5).  
This data demonstrate that the dampened response to type I IFNs as a result of 
IFNAR1*557Gluext*46 is insufficient to control CMV replication in vitro and contributes to the patient 
increased susceptibility to the virus. 
 
 
 
(*) This data was kindly generated by Dr. David M. Knipe and Maggie Angelova, PhD. 
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Figure 5. Proband derived fibroblasts are unable to control CMV replication after IFN-" 
pre-treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
Proband (IFNAR1*557next*46) and healthy control (WT IFNAR1) derived fibroblasts were stimulated 
with IFN-" for 12 hours prior to infection with CMV. Expression of the CMV IE1 and IE2 proteins 
was evaluated by immunofluorescence 16 hours post infection. 
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2.4. DISCUSSION 
 
 We report a novel multigenic cause of primary immunodeficiency affecting the cellular 
response to IFNs. Using WES we identified two candidate homozygous mutations affecting the 
IFNGR2 and the IFNAR1 genes. The IFNGR2C266fs mutation causes the expression of a 
truncated protein that lacks the intracellular domains necessary for signalling downstream of the 
receptor and abrogates the cellular response to IFN-!. The IFNAR1*557Gluext*46 mutation adds 46 
novel amino acids to the C-terminus of IFNAR1. The presence of these extra 46 amino acids 
decreases phosphorylation of STAT1 and STAT2 and nuclear translocation of pSTAT1/pSTAT2 
dimers, significantly decreasing the expression of ISGs after stimulation with IFN-" and infection 
with CMV and the effectiveness of the anti-viral state in blocking viral replication. These results 
confirm the pathogenic nature of both candidate mutations and their role on the proband’s 
susceptibility to infection with Mycobacterium tuberculosis and CMV. 
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Supplementary Table 1. HLH diagnostic criteria in the patient. 
 
Diagnostic criteria for HLH (2004)50 Findings in Patient 
Fever Present 
Splenomegaly Present 
Cytopenias 
    Hemoglobin < 90 g/L 
    Platelets < 100 x 109/L   
    Neutrophils < 1 x 109/L 
 
9.6g/L 
21.5 x 109/L 
9.66 x 109/L 
Hypertriglyceridemia and/or hypofibrinogenemia 
    Triglycerides ) 3.0 mmol/L 
    Fibrinogen * 1.5 g/L 
 
7.5mmol/L 
1.5 g/L 
Hemophagocytosis in bone marrow, spleen or lymph nodes Present 
Low or absent NK cell activity Not analyzed 
Ferritin ) 500 µg/L 4,000 µg/L 
Soluble CD25 ) 2,400 U/mL 
Pathogenic mutations in genes causing HLHi 
6,500 U/mL 
Not found 
 
i No mutations in the PRF1, UNC13D, STX11 or STXBP2 genes. 
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Supplementary Table 2. Homozygous variants found in the patient using WES. 
 
Gene 
 
Chromosome Mutation 
start 
Mutation 
end 
Reference 
base 
Altered 
 base(s) 
TCTEX1D1 1 67242069 67242069 - C 
DDAH1 1 85930490 85930490 A G 
FAM171B 2 187559029 187559029 - CAG 
SLC38A3 3 50251833 50251833 - G 
MUC4 3 195518112 195518112 - GTCTCCTGCGTAACA 
ZNF595 4 85995 85995 - A 
DOPEY1 6 83845388 83845388 G T 
LFNG 7 2552882 2552882 GATG - 
IQCE 7 2598818 2598818 G A 
AOAH 7 36552790 36552790 - T 
UPK3B 7 76144774 76144774 A T 
UPK3B 7 76144775 76144775 T C 
AGAP3 7 150783922 150783922 T G 
RHOBTB2 8 22864881 22864881 G A 
RASSF7 11 562408 562408 T C 
C11orf40 11 4592708 4592708 - AG 
SLC6A12 12 310979 310979 C T 
WNK1 12 974308 974308 - C 
AKAP3 12 4736727 4736727 T G 
ANKLE2 12 133338366 133338366 C T 
MLNR 13 49796269 49796269 TC - 
FLVCR2 14 76045601 76045601 A G 
PKD1L3 16 71981414 71981414 - TTTGG 
OR7C2 19 15052983 15052983 - ATC 
LTBP4 19 41123093 41123093 - G 
GCFC1 21 34143903 34143903 T G 
IFNAR1 21 34727852 34727852 ATGACC - 
IFNGR2 21 34805097 34805097 T - 
CARD10 22 37904680 37904680 G A 
BAIAP2L2 22 38485609 38485609 C T 
DMD X 31893387 31893387 T C 
ITIH6 X 54777534 54777534 C T 
ITIH6 X 54785283 54785283 A T 
SLC16A2 X 73641251 73641251 A T 
TCEAL6 X 101395784 101395784 C G 
SERPINA7 X 105279192 105279192 AA - 
RBMXL3 X 114424364 114424364 - C 
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Supplementary Figure 1. Sanger sequencing confirmation of the carrier state in the 
proband’s parents for the IFNGR2 and IFNAR1 mutations. 
 
 
A, Sanger sequencing demonstrating the heterozygous state in the proband’s parents for the 
IFNGR2 mutation (798delT). B, Sanger sequencing demonstrating the heterozygous state in the 
proband’s parents for the IFNGAR1 mutation (1671_1821del). Sequencing of a control subject 
is included. WT = wild type, Mut = mutant. 
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Supplementary Figure 2. cDNA Sanger sequencing confirmation of the predicted 
modifications to the protein structure as a result of the IFNGR2 and IFNAR1 mutations. 
 
 
A, cDNA Sanger sequencing confirming the premature truncation at residue 270 of the 
IFNGR2C266fs. B, cDNA Sanger sequencing confirming the addition of a novel amino acid 
sequence to the IFNAR1*557Gluext*46 protein C terminus. 
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Supplementary Figure 3. IFNAR1*557Gluext*46 expression does not affect CMV entry or 
baseline levels of IFI16 expression. 
 
 
A, CMV entry was evaluated by qt-PCR quantification of IE1 after an adsorption time of 2 hours. 
B, Immunofluorescence evaluation of baseline expression levels of IFI16 in proband 
(IFNAR1*557Gluext*46) and healthy control (WT IFNAR1) derived fibroblasts. 
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3. CHAPTER 3: DISCUSSION AND PERSPECTIVES 
3.1. DISCUSSION 
 
 We here report a patient with dual novel defects in the IFN pathway: a nonsense 
mutation in IFNGR2 and a mutation in IFNAR1 that adds 46 amino acids to the protein’s C-
terminus. IFNGR2C266fs was expresed at a significantly lower level compared to wild-type 
IFNGR2 in control cells and the patient’s fibroblasts has no STAT1 phosphorylation or HLA-DR 
upregulation in response to IFN-!, which is consistent with his susceptibility to disseminated 
Mycobaterium tuberculosis. However, the patient’s CMV viremia is not a common feature of 
MSMD. Although a small subgroup of ISGs can be induced in response to both type I IFNs and 
IFN-!, type I IFNs activate transcription of a wider set of genes important for host immunity 
against viruses9. We found that the patient’s IFNAR1 mutation resulted in impaired intracellular 
signaling downstream of IFN-α stimulation and defective expression of ISGs crucial for 
controlling CMV51. 
 Mutations that affect the IFNGR2 gene are a rare cause of MSMD and account for only 
4% of the cases reported to date52. The expression of IFNGR2 is essential for the intracellular 
signaling events in response to IFN-!. IFNGR2 lacks intrinsic enzymatic activity and its 
signaling function depends on the association with the kinase Jak2, which binds to two 
sequences between aminoacids 284-295 within the receptor’s intracellular domain53. We have 
shown that the IFNGR2C266fs mutant protein is truncated at residue 270, thus eliminating both 
Jak2 binding sequences. Loss of the 67 C-terminal amino acids  of IFNGR2 results in impaired 
protein expression and a lack of response to IFN-!, demonstrating that the patient has a novel 
genetic cause of autosomal recessive MSMD.  
 There have been no previous reports of patients with MSMD presenting with HLH. Our 
proband’s secondary HLH occurred in the setting of disseminated infections with multiple 
organisms: Mycobaterium tuberculosis, Streptococcus viridans, and CMV. MSMD patients are 
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considered immunocompetent to pathogens other than Mycobacteria and Salmonella. A few 
case reports of patients with MSMD have been reported to have infections with other 
organisms, but it was not known if the patient’s susceptibility to these organisms arose from the 
genetic defects underlying their MSMD. The unusual clinical presentation of the proband, his 
history of multi-organism sepsis and the lack of reported cases of HLH secondary to 
Mycobacteria in MSMD patients prompted us to further analyze the potential role of secondary 
mutations on this patient’s phenotype. Given the history of parental consanguinity, an 
autosomal recessive pattern of inheritance was anticipated for any disease causing mutations. 
Our unbiased whole exome sequencing approach identified the mutation in IFNAR1 as the 
second pathogenic mutation in this patient. The IFNAR1*557Gluext*46 mutation replaces the 
protein’s native stop codon with 46 novel C-terminal amino acids, while otherwise preserving 
the amino acid sequence of the wild-type receptor. We have demonstrated that the addition of 
the 46 extra amino acids in IFNAR1*557Gluext*46 does not affect protein expression. Despite 
normal surface expression levels of the mutant receptor, we found that signaling events 
downstream of IFNAR1*557Gluext*46 led to decreased phosphorylation of STAT1 and STAT2 and 
pSTAT1 nuclear translocation after stimulation with IFN-".  
Host immunity against viral infection depends on the expression of ISG downstream of 
the IFNAR. The role of many ISG in the antiviral response has yet to be studied; however, the 
IFIT family of genes has been shown to be important for mounting an effective response against 
viruses by efficiently blocking viral replication26, 27, 28. We have shown that defective signaling 
downstream of IFNAR1*557Gluext*46 significantly impairs normal expression of the ISG in response 
to IFN-" stimulation and viral infection. The DNA sensor IFI16 is an ISG important for the 
cellular response to CMV and HSV, after sensing viral DNA, IFI16 induces IFN-% expression via 
the STING/TBK1/IRF-3 pathway54 and interestingly, induction of IFI16 expression is important 
for restriction of CMV replication55. We have demonstrated that in spite of similar baseline 
expression levels of IFI16 in patient and control fibroblasts, cells expressing IFNAR1*557Gluext*46 
 &+"
show decreased upregulation of IFI16 after infection with CMV or HSV-1 d109, this defective 
response might play a role in the proband’s susceptibility to CMV facilitating CMV replication. 
Upregulation of the IFIT1 and IFIT2 genes has been reported previously in human fibroblasts in 
response to CMV infection29, 30 and the normal response to type I IFNs is crucial for controlling 
CMV spread and replication in vitro51. The exact mechanism by which the IFIT family members 
contribute to controlling CMV infections has not yet been definitively proven. It has been 
proposed that that expression of the IFIT genes blocks CMV replication by nonspecifically 
decreasing cellular translation or by interacting with CMV specific proteins as has been 
previously shown for other DNA viruses27. Using an in vitro model of viral infection with CMV, 
we have demonstrated that despite the partial upregulation of ISGs downstream of 
IFNAR1*557Gluext*46, the dampened cellular response to type I IFNs fails to mount an anti-viral 
state that effectively prevents viral replication. Additionally, type I IFNs induce the expression of 
class I HLA genes and stimulate NK and CD8+ T cell mediated cytotoxicity10, thereby promoting 
killing of virus infected cells. The defective intracellular signaling events downstream of 
IFNAR1*557Gluext*46 may favor CMV replication by diminishing the induction of ISG that specifically 
block viral replication and by affecting the normal cytotoxic response against CMV infected cells 
in vivo.  
To our knowledge, this is the first report of a patient with a mutation in IFNAR1. A 
kindred with a mutation in the IFNAR2 gene has been previously reported. Although, in in vitro 
studies have shown the critical role of type I IFNs in the response against CMV, patients lacking 
IFNAR2 have been reported to control CMV without developing clinically relevant symptoms17. 
The immunocompetence to CMV observed in IFNAR2 deficient patients may be explained by 
their normal response to IFN-! and partial complementation of their defective induction of ISG in 
response to type I IFNs by IFN-! mediated formation of ISGF3 complexes. IFNAR2 and STAT2 
deficient patients17,18 have been reported to develop fatal vaccine strain related measles 
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encephalopathy after receiving the MMR vaccine. However, our proband had no complications 
after MMR vaccination. The residual signaling and ISG gene expression downstream of 
IFNAR1*557Gluext*46 in our proband may have been sufficient for providing immunity against 
attenuated, but not wild type, viruses. In contrast, previously reported mutations in IFNAR2 and 
STAT2 led to complete abrogation of the cellular response to IFN-". We hypothesize that the 
high copy number of CMV in the proband may have been due to his dual defect in IFN 
signaling, specifically, the impaired upregulation of ISGs downstream of IFNAR1*557Gluext*46 and 
the failure of IFNGR signaling to complement this defective response. To assess the 
contribution of IFNAR1*557Gluext*46 in controlling CMV viremia, we are currently performing in vitro 
studies of CMV replication in patient-derived fibroblasts with and without reconstitution with the 
wild type IFNAR1 gene. 
In addition to CMV viremia, the proband presented with Streptococcus viridans 
bacteremia. The role of type I IFNs in the immune response to virus has been widely studied; 
however, their role in maintaining host immunity against bacterial pathogens has yet to be 
clarified7, 56. The effect of the IFN pathways in the response to mycobacteria has been studied 
using IFNAR-/-, IFNGR-/- or IFNAR-/-IFNGR-/- double knockout mice. Group B streptococci (GBS) 
infection of IFNAR- or IFNGR-deficient mice showed increased lethality and bacterial burden 
when compared to wild type mice. IFNAR-/-IFNGR-/- double knockout mice died within the first 
three days post infection, demonstrating significantly more susceptibility to GBS than either of 
the IFNAR-/- or IFNGR-/- single knockout mice57. These data suggest that type I IFNs contribute 
to host immunity against extracellular bacteria, although the mechanisms are not yet 
understood. Neither the IFNAR-/- mice nor the patients with IFNAR2 or STAT2 deficiency have 
been reported to develop mycobacterial infections17, 18, indicating that the immune response to 
mycobacteria does not depend on type I IFNs. In contrast, the genetic defects associated with 
MSMD indicate the critical contribution of the type II IFN signaling pathways to immunity against 
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mycobacteria. 
In summary, we have identified a primary immunodeficiency arising from dual defects in 
the type I and type II IFN pathways in a patient with sepsis due to multiple pathogens. We have 
shown that the impaired response to type I IFNs downstream of IFNAR1*557Gluext*46 fails to 
establish an effective anti-viral state and promotes CMV infection; furthermore, the patient’s 
defect in IFNGR2 completely abrogates the response to IFN-!, which is critical for the immune 
response against mycobacteria. While PIDs have been classically considered monogenic 
diseases58, our work demonstrates the utility of unbiased next generation sequencing 
technologies in identifying multigenic causes of immunodeficiency.   
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3.2. LIMITATIONS 
 We have shown that the patient’s fibroblasts have impaired phosphorylation of 
STAT1 and STAT2 as well as impaired nuclear translocation of pSTAT2. We hypothesized that 
the 46 novel C-terminal amino acids of IFNAR1*557Gluext*46 sequesters the pSTAT1/pSTAT2 
heterodimer and impairs translocation of the heterodimer to the nucleus, thereby preventing 
subsequent binding of unphosphorylated STAT1 and STAT2 proteins to the receptor. To prove 
this, we performed co-immunoprecipitation experiments to quantify the amount of pSTAT1 and 
pSTAT2 bound to IFNAR1 after stimulating patient and control fibroblasts with IFN-". However, 
as previously reported by other studies59, the weak interaction between the IFNAR and the 
pSTAT1/pSTAT2 heterodimer is not detectable by co-immunoprecipitation of proteins using 
primary cells.  The use of an over-expression system is an alternative approach to evaluate the 
interaction between IFNAR1 and the pSTAT1/pSTAT2 dimer. Since the patient’s fibroblasts 
demonstrated residual expression of a mutant IFNGR2 protein as well as levels of 
IFNAR1*557Gluext*46 equivalent to that of wild-type IFNAR1, this experiment requires transfection of 
a cell line that lacks wild-type forms of the human IFNGR2 and IFNAR1. These experiments are 
beyond the scope of the current study. The use of paraformaldehyde fixation previous to 
immunoprecipitation could be an additional approach to evaluate the interaction between 
IFNAR1*557Gluext*46 and the pSTAT1/pSTAT2 dimer.  
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3.3. FUTURE RESEARCH 
 The function of type I IFNs expands beyond the establishment of the anti-viral state. 
Type I IFNs have been reported to possess anti-inflammatory properties and are currently used 
for the treatment of inflammatory conditions like multiple sclerosis60 and familial Mediterranean 
fever61. Type I IFNs have been shown to decrease the production of IL-1% by decreasing the 
production of proIL-1% in an IL-10 mediated, STAT3 dependent fashion62. Repression of the 
NLRP3 inflammasome activity has been described in monocytes after treatment with type I 
IFNs. Repression of the NLRP3 inflammasome has been shown to depend on STAT1 
phosphorylation, which suggests it is that the underlying mechanism involves the expression of 
a yet unidentified ISG62. The AIM2 inflammasome is also modulated by type I IFNs via induction 
of the ISG IFI16, binding of IFI16 to AIM2 prevents the interaction between AIM2 and ASC, 
hence the blocking AIM2 inflammasome assembly63. 
 The development of secondary HLH is uncharacteristic of patients with PIDs and has not 
been described previously in patients with MSMD. In patients with secondary HLH, the 
uncontrolled infection induces a cytokine storm that causes over activation of the monocyte-
macrophage compartment. Human studies on familiar HLH and HLH secondary to systemic 
onset juvenile idiopathic arthritis (sJIA) have suggested a role for IL-1 signaling in macrophage 
over-activation64, 65. The administration of Anakinra®, a recombinant IL-1 receptor antagonist, 
has been reported to be beneficial in the treatment of HLH secondary to sJIA66, 67. We 
hypothesize that the patient’s defect in Type I IFN signaling leads to increased activation of the 
AIM2 inflammasome in response to infection with CMV, thereby increasing his susceptibility to 
develop HLH. To test this hypothesis, we are quantifying IL-1% production after CMV infection of 
fibroblasts from the patient and controls. These studies will determine if a deficiency in IFNAR1 
 '&"
results not only in a primary immunodeficiency, but also an autoinflammatory state. 
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